These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33054118)

  • 1. Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration.
    Stephens DM; Boucher K; Kander E; Parikh SA; Parry EM; Shadman M; Pagel JM; Cooperrider J; Rhodes J; Mato A; Winter A; Hill B; Gaballa S; Danilov A; Phillips T; Brander DM; Smith SM; Davids M; Rogers K; Glenn MJ; Byrd JC
    Haematologica; 2021 Nov; 106(11):2845-2852. PubMed ID: 33054118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
    Mauro FR; Galieni P; Tedeschi A; Laurenti L; Del Poeta G; Reda G; Motta M; Gozzetti A; Murru R; Caputo MD; Campanelli M; Frustaci AM; Innocenti I; Raponi S; Guarini A; Morabito F; Foà R; Gentile M
    Am J Hematol; 2017 Jun; 92(6):529-535. PubMed ID: 28295527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-growing follicle density is increased following adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy in the adult human ovary.
    McLaughlin M; Kelsey TW; Wallace WH; Anderson RA; Telfer EE
    Hum Reprod; 2017 Jan; 32(1):165-174. PubMed ID: 27923859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
    Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
    J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
    Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
    Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution.
    de Armas S; Huertas-Ayala C; Chan RY; Chi YY; Huh WW; Termuhlen A; Gaynon PS; Kovach AE; Doan A
    Pediatr Blood Cancer; 2022 May; 69(5):e29601. PubMed ID: 35187850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hodgkin lymphoma transformation of chronic lymphocytic leukemia-A real life data from the Polish Lymphoma Research Group.
    Drozd-Sokołowska J; Zaucha JM; Żółtak T; Jamroziak K; Grzybowska-Izydorczyk O; Witkowska M; Waszczuk-Gajda A; Kaźmierczak M; Szczepaniak A; Subocz E; Knopińska-Posłuszny W; Hołojda J; Kopińska A; Hus I; Rybka J; Wołowiec D; Kwiatkowski J; Hałaburda K; Smolewski P; Giebel S; Wiktor-Jędrzejczak W
    Hematol Oncol; 2019 Oct; 37(4):383-391. PubMed ID: 31026087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consolidative radiation therapy for stage III Hodgkin lymphoma in patients who achieve complete response after ABVD chemotherapy.
    Phan J; Mazloom A; Abboud M; Salehpour M; Reed V; Zreik T; Shihadeh F; Fisher C; Wogan C; Dabaja B
    Am J Clin Oncol; 2011 Oct; 34(5):499-505. PubMed ID: 21537149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
    André MPE; Carde P; Viviani S; Bellei M; Fortpied C; Hutchings M; Gianni AM; Brice P; Casasnovas O; Gobbi PG; Zinzani PL; Dupuis J; Iannitto E; Rambaldi A; Brière J; Clément-Filliatre L; Heczko M; Valagussa P; Douxfils J; Depaus J; Federico M; Mounier N
    Cancer Med; 2020 Sep; 9(18):6565-6575. PubMed ID: 32710498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.
    Hay AE; Klimm B; Chen BE; Goergen H; Shepherd LE; Fuchs M; Gospodarowicz MK; Borchmann P; Connors JM; Markova J; Crump M; Lohri A; Winter JN; Dörken B; Pearcey RG; Diehl V; Horning SJ; Eich HT; Engert A; Meyer RM;
    Ann Oncol; 2013 Dec; 24(12):3065-9. PubMed ID: 24121121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
    Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
    Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience.
    Rose A; Grajales-Cruz A; Lim A; Todd A; Bello C; Shah B; Chavez J; Pinilla-Ibartz J; Saeed H; Sandoval-Sus J; Isenalumhe L; Sokol L
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):132-138. PubMed ID: 32950461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
    N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
    Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
    Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of ABVD chemotherapy on ovarian reserve after fertility preservation in reproductive-aged women with Hodgkin lymphoma.
    Policiano C; Subirá J; Aguilar A; Monzó S; Iniesta I; Rubio Rubio JM
    J Assist Reprod Genet; 2020 Jul; 37(7):1755-1761. PubMed ID: 32488563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
    Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
    J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial.
    Russell J; Collins A; Fowler A; Karanth M; Saha C; Docherty S; Padayatty J; Maw K; Lentell I; Cooke L; Hodson A; Shah N; Sadullah S; Grigoropoulos N; Qian W; Kirkwood AA; Uttenthal BJ; Johnson P; Follows GA
    Ann Hematol; 2021 Apr; 100(4):1049-1058. PubMed ID: 33641019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era.
    Keller SF; Kelly JL; Sensenig E; Andreozzi J; Oliva J; Rich L; Constine L; Becker M; Phillips G; Liesveld J; Fisher RI; Bernstein SH; Friedberg JW
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):640-7. PubMed ID: 21871246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia.
    Zhu K; Jamroz A; Huang S; Villa D; Freeman CL; Scott DW; Slack G; Sehn LH; Connors JM; Toze CL; Savage KJ; Gerrie AS
    Br J Haematol; 2022 Aug; 198(4):684-692. PubMed ID: 35567407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.